

IgA Nephropathy Drugs Market to Grow at 18.1% CAGR Driven by Biologic Innovations and FDA Approvals | DataM Intelligence

The IgA Nephropathy drugs market is set for 18.1% CAGR growth, led by biologics, FDA approvals, and major pharma R&D efforts worldwide.

NEW YORK, NY, UNITED STATES, May 30, 2025 /EINPresswire.com/ -- Market Overview:

The [IgA Nephropathy Drugs Market](#) is expected to expand at a CAGR of 18.1% between 2024 and 2031. Also known as Berger's disease, IgA Nephropathy is a long-term kidney condition characterized by the accumulation of immunoglobulin A in the kidneys, causing inflammation and progressive kidney damage.



Market Drivers:



The rising wave of biologic drug approvals and global R&D efforts are accelerating breakthroughs in IgA nephropathy treatment like never before."

DataM Intelligence

Rising Prevalence of Kidney Disorders: Increased incidence of chronic kidney diseases worldwide, particularly in aging populations, is fueling demand.

Breakthrough Drug Approvals: Regulatory approvals for first-in-class drugs, especially from the FDA and EMA, are accelerating market momentum.

Advancements in Biologics and Gene Therapies: Biologic formulations are offering new avenues for long-term

disease management.

Strong Pipeline and R&D Investment: Key players are actively developing novel therapeutics with

high specificity and fewer side effects.

Government and Private Funding Initiatives: Supportive policies and research grants are enhancing drug development across key regions.

Get Premium Sample Report : <https://www.datamintelligence.com/download-sample/iga-nephropathy-drugs-market>

Key Players in the Market:

The landscape is dominated by innovative pharmaceutical companies focused on nephrology and rare diseases:

Calliditas Therapeutics AB

Traverse Therapeutics, Inc.

Omeros Corporation

Vera Therapeutics

MorphoSys AG

Otsuka Pharmaceutical

Alembic Pharmaceuticals Limited

Everest Medicines

Novartis AG

Alexion Pharmaceuticals, Inc.

These companies are involved in advanced clinical trials, partnerships, and strategic acquisitions to bring novel therapies to market.

Market Segmentation:

By Drug Class:

Corticosteroids

Immunosuppressants

ACE Inhibitors & ARBs

Biologics & Monoclonal Antibodies
Others

By Route of Administration:

Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Europe
Asia-Pacific
Latin America
Middle East & Africa

Latest News of USA:

In April 2024, the FDA approved Nefecon by Calliditas Therapeutics, the first therapy specifically designed for IgA nephropathy.

Traverse Therapeutics expanded U.S. access to Sparsentan following promising Phase 3 trial outcomes.

Vera Therapeutics initiated an expanded access program in the U.S. for Atacicept, a dual-targeting biologic for IgAN.

Latest News of Japan:

Otsuka Pharmaceutical announced a strategic partnership with a local biotech firm to advance IgAN gene therapies.

In February 2024, the Japanese Ministry of Health fast-tracked review of Calliditas' Nefecon, aiming for mid-year approval.

Novartis Japan initiated a regional study on the long-term impact of SGLT2 inhibitors on IgA nephropathy patients.

Key Developments

Calliditas' Nefecon receives FDA approval as the first targeted therapy for IgA Nephropathy.

Traverse Therapeutics launches Phase 3 trial results of Sparsentan with positive proteinuria reduction data.

Vera Therapeutics expands clinical trial sites across North America and Europe for Atacicept.

MorphoSys collaborates with academic institutions for biomarker research in nephrology.

Alembic Pharmaceuticals enters the nephrology biosimilars market.

Novartis reports early-stage success of biologic IgAN therapy in Japan.

Conclusion:

The IgA Nephropathy drugs market is on a high-growth trajectory, driven by a surge in biologics, strategic R&D efforts, and supportive regulatory frameworks. With global players pushing forward innovative treatment options and expanding access, the therapeutic outlook for IgA nephropathy is becoming increasingly hopeful. The coming years are expected to witness continued breakthroughs, making early diagnosis and personalized care more feasible for patients across the globe.

Related Reports :

[Immunosuppressants Drugs Market Analysis 2024 - 2031](#)

[Intravenous Immunoglobulin Market Outlook 2024 - 2031](#)

Sai Kumar

DataM Intelligence 4market Research LLP

+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/817482579>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

